Company intelligence / Profile preview

IRIDEX

Mountain View, California, United Statesiridex.com ↗

Ownership: Public · IRIX
Employees: ~178
Development stage: Commercial

Overview

Iridex’s proprietary MicroPulse® laser technology has demonstrated safety and efficacy in treating sight-threatening eye conditions such as glaucoma and various retinal diseases. The company continues to expand its clinical evidence base with ongoing studies like the MicroPulse TLT Clinical Study in collaboration with Imperial College Healthcare NHS Trust. Recent launches include new generations of their core laser systems for retina disorders and glaucoma.

Therapeutic areas: Ophthalmology
Modalities: DeviceLaser-based therapy
Industry: Therapeutic Medical Devices

Partnerships

Collaboration with Imperial College Healthcare NHS Trust on clinical studies

Beyond the preview

Go deeper on IRIDEX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IRIDEX.

Explore the full profile